NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.42B
This Quarter Return
-6.17%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$1.65B
AUM Growth
+$1.65B
(-18%)
Cap. Flow
-$194M
Cap. Flow
% of AUM
-11.72%
Top 10 Holdings %
Top 10 Hldgs %
71.92%
Holding
40
New
3
Increased
6
Reduced
6
Closed
6
Top Buys
| 1 |
Recursion Pharmaceuticals
RXRX
|
$68.4M |
| 2 |
ASML
ASML
|
$22.5M |
| 3 |
CBLL
CeriBell, Inc. Common Stock
CBLL
|
$8.51M |
| 4 |
Mersana Therapeutics
MRSN
|
$6.08M |
| 5 |
ZBIO
Zenas BioPharma, Inc. Common Stock
ZBIO
|
$3.69M |
Top Sells
| 1 |
Corcept Therapeutics
CORT
|
$112M |
| 2 |
Cable One
CABO
|
$41.4M |
| 3 |
Brookfield
BN
|
$39.8M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$32.6M |
| 5 |
Brookfield Asset Management
BAM
|
$29.7M |
Sector Composition
| 1 | Healthcare | 55.4% |
| 2 | Technology | 13.01% |
| 3 | Financials | 9.73% |
| 4 | Consumer Discretionary | 2.32% |
| 5 | Industrials | 1.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard Total Stock Market ETF
VTI
$526B
| $301M | 18.22% | 1,038,550 | – | – |
|
|
2
Brookfield
BN
$98.3B
| $161M | 9.73% | 2,798,830 -692,400 | -20% | -$39.8M |
|
|
TEM
3
Tempus AI, Inc. Class A Common Stock
TEM
$13.2B
| $138M | 8.33% | 4,074,419 | – | – |
|
4
Edgewise Therapeutics
EWTX
$1.51B
| $134M | 8.08% | 5,000,000 -549,900 | -10% | -$14.7M |
|
|
5
ASML
ASML
$292B
| $115M | 6.96% | 165,836 +32,500 | +24% | +$22.5M |
|
6
Salesforce
CRM
$245B
| $98.3M | 5.95% | 293,901 -74,659 | -20% | -$25M |
|
|
7
Recursion Pharmaceuticals
RXRX
$2.04B
| $68.4M | 4.14% | +10,114,633 | New | +$68.4M |
|
8
Mirum Pharmaceuticals
MIRM
$3.71B
| $62M | 3.76% | 1,500,000 | – | – |
|
9
Vaxcyte
PCVX
$4B
| $61.4M | 3.72% | 750,000 | – | – |
|
10
Insmed
INSM
$28.8B
| $50M | 3.03% | 724,666 | – | – |
|
11
Crinetics Pharmaceuticals
CRNX
$2.92B
| $49.1M | 2.97% | 960,215 -39,785 | -4% | -$2.03M |
|
12
Viridian Therapeutics
VRDN
$1.5B
| $43.1M | 2.61% | 2,250,000 -135,000 | -6% | -$2.59M |
|
13
ArriVent BioPharma
AVBP
$776M
| $40.5M | 2.45% | 1,520,627 +15,312 | +1% | +$408K |
|
14
Alibaba
BABA
$322B
| $38.4M | 2.32% | 452,327 -48,500 | -10% | -$4.11M |
|
15
Pharvaris
PHVS
$1.39B
| $33.1M | 2% | 1,725,000 | – | – |
|
16
BioMarin Pharmaceuticals
BMRN
$11.2B
| $32.2M | 1.95% | 490,000 | – | – |
|
17
Merus
MRUS
$4.98B
| $31.5M | 1.91% | 750,000 +50,000 | +7% | +$2.1M |
|
18
Celldex Therapeutics
CLDX
$1.47B
| $25.3M | 1.53% | 1,000,000 +36,337 | +4% | +$918K |
|
|
CRGX
19
DELISTED
CARGO Therapeutics
CRGX
| $24M | 1.45% | 1,663,724 +119,724 | +8% | +$1.73M |
|
20
Amicus Therapeutics
FOLD
$2.34B
| $23.6M | 1.43% | 2,500,000 | – | – |
|
21
LanzaTech
LNZA
$49.1M
| $21.7M | 1.31% | 15,814,845 | – | – |
|
|
BPMC
22
DELISTED
Blueprint Medicines
BPMC
| $15.3M | 0.92% | 175,000 | – | – |
|
23
Rocket Pharmaceuticals
RCKT
$354M
| $13.8M | 0.84% | 1,100,000 | – | – |
|
|
VERV
24
DELISTED
Verve Therapeutics
VERV
| $13.5M | 0.82% | 2,400,000 | – | – |
|
|
ZBIO
25
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $13.1M | 0.79% | 1,600,000 +450,000 | +39% | +$3.69M |
|